DV Trading LLC Purchases Shares of 240,963 OnKure Therapeutics, Inc. $OKUR

DV Trading LLC acquired a new stake in shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 240,963 shares of the company’s stock, valued at approximately $998,000.

Other large investors have also recently modified their holdings of the company. ADAR1 Capital Management LLC lifted its stake in shares of OnKure Therapeutics by 140.1% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,434,941 shares of the company’s stock valued at $10,081,000 after acquiring an additional 1,420,783 shares during the last quarter. Vivo Capital LLC purchased a new stake in OnKure Therapeutics during the 1st quarter valued at about $7,981,000. Shay Capital LLC grew its position in OnKure Therapeutics by 17.4% during the 3rd quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock worth $2,524,000 after acquiring an additional 135,888 shares during the last quarter. Prosight Management LP grew its position in OnKure Therapeutics by 204.9% during the 4th quarter. Prosight Management LP now owns 816,909 shares of the company’s stock worth $2,369,000 after acquiring an additional 548,950 shares during the last quarter. Finally, Rosalind Advisors Inc. purchased a new position in OnKure Therapeutics in the 4th quarter worth approximately $2,118,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Trading Down 4.5%

OnKure Therapeutics stock opened at $3.82 on Friday. The firm has a market cap of $154.33 million, a P/E ratio of -0.88 and a beta of 0.27. OnKure Therapeutics, Inc. has a 1-year low of $1.91 and a 1-year high of $5.38. The firm has a 50-day moving average of $4.26 and a 200-day moving average of $3.80.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.37). Research analysts forecast that OnKure Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

OKUR has been the subject of several recent research reports. HC Wainwright lowered their price objective on OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a research report on Monday, July 20th. JonesTrading cut shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, Weiss Ratings downgraded shares of OnKure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $21.00.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.